ESR2 and metastatic melanoma: On the other hand, oestradiol and oestrogen receptor β (ERβ) agonists inhibit melanoma cell proliferation [54, 55] and ERβ, which is the main subtype in melanocytes, is reduced in melanoma cells and is lowest in invasive and metastatic melanoma [56, 57].